Información del artículo
El Texto completo está disponible en PDF
References
[1.]
F.D. Martínez.
Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma.
Pediatr Infect Dis J, 22 (2003), pp. 76-82
[2.]
L.E. Dickens, P.L. Collins, G.W. Wertz.
Transcriptional mapping of human respiratory syncytial virus.
J Virol, 52 (1984), pp. 364-369
[3.]
P.L. Ogra.
Respiratory syncytial virus: the virus, the disease and the immune response.
Paediatr Respir Rev, 5 (2004), pp. 119-126
[4.]
P.L. Collins, L.E. Dickens, A. Buckler-White, R.A. Olmsted, M.K. Spriggs, E. Camargo, et al.
Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.
Proc Natl Acad Sci USA, 83 (1986), pp. 4594-4598
[5.]
R.E. Blount Jr., J.A. Morris, R.E. Savage.
Recovery of cytopathogenic agent from chimpanzees with coryza.
Proc Soc Exp Biol Med, 92 (1956), pp. 544-549
[6.]
S. Psarras, N.G. Papadopoulos, S.L. Johnston.
Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing.
Paediatr Respir Rev, 5 (2004), pp. 179-184
[7.]
A.R. Falsey, C.K. Cunningham, W.H. Barker, R.W. Kouides, J.B. Yuen, M. Menegus, et al.
Respiratory syncytial virus and influenza A infections in the hospitalized elderly.
J Infect Dis, 172 (1995), pp. 389-394
[8.]
S.F. Dowell, L.J. Anderson, H.E. Gary Jr., D.D. Erdman, J.F. Plouffe, T.M. File Jr., et al.
Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults.
J Infect Dis, 174 (1996), pp. 456-462
[9.]
M. Hashem, C.B. Hall.
Respiratory syncytial virus in healthy adults: the cost of a cold.
J Clin Virol, 27 (2003), pp. 14-21
[10.]
W.J. Hall, C.B. Hall, D.M. Speers.
Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies.
Ann Intern Med, 88 (1978), pp. 203-205
[11.]
D.K. Shay, R.C. Holman, R.D. Newman, L.L. Liu, J.W. Stout, L.J. Anderson.
Bronchiolitis-associated hospitalizations among US children, 1980-1996.
JAMA, 282 (1999), pp. 1440-1446
[12.]
D. Vicente, M. Montes, G. Cilla, E.G. Pérez-Yarza, E. Pérez-Trallero.
Hospitalization for respiratory syncytial virus in the paediatric population in Spain.
Epidemiol Infect, 131 (2003), pp. 867-872
[13.]
C.R. Pullan, E.N. Hey.
Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy.
Br Med J (Clin Res Ed), 284 (1982), pp. 1665-1669
[14.]
N. Sigurs, R. Bjarnason, F. Sigurbergsson, B. Kjellman.
Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.
Am J Respir Crit Care Med, 161 (2000), pp. 1501-1507
[15.]
F.D. Martinez, A.L. Wright, L.M. Taussig, C.J. Holberg, M. Halonen, W.J. Morgan.
Asthma and wheezing in the first six years of life. The Group Health Medical Associates.
N Engl J Med, 332 (1995), pp. 133-138
[16.]
J.C. Rooney, H.E. Williams.
The relationship between proved viral bronchiolitis and subsequent wheezing.
J Pediatr, 79 (1971), pp. 744-747
[17.]
C.B. Hall.
Respiratory syncytial virus and parainfluenza virus.
N Engl J Med, 344 (2001), pp. 1917-1928
[18.]
R.T. Stein, D. Sherrill, W.J. Morgan, C.J. Holberg, M. Halonen, L.M. Taussig, et al.
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.
Lancet, 354 (1999), pp. 541-545
[19.]
C.B. Hall, W.J. Hall, C.L. Gala, F.B. MaGill, J.P. Leddy.
Long-term prospective study in children after respiratory syncytial virus infection.
J Pediatr, 105 (1984), pp. 358-364
[20.]
J.Y. Mok, H. Simpson.
Outcome for acute bronchitis, bronchiolitis, and pneumonia in infancy.
Arch Dis Child, 59 (1984), pp. 306-309
[21.]
L. Bont, W.M. Aalderen, J.L. Kimpen.
Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis.
Paediatr Respir Rev, 1 (2000), pp. 221-227
[22.]
R.G. Sommerville.
Respiratory syncytial virus in acute exacerbations of chronic bronchitis.
Lancet, 47 (1963), pp. 1247-1248
[23.]
J. Castro, J.J. Telleria, A. Blanco-Quiros.
Susceptibility genes for asthma and allergy: hits and questions.
J Investig Allergol Clin Immunol, 11 (2001), pp. 73-78
[24.]
T. Goetghebuer, K. Isles, C. Moore, A. Thomson, D. Kwiatkowski, J. Hull.
Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis.
Clin Exp Allergy, 34 (2004), pp. 801-803
[25.]
J. Hull, A. Thomson, D. Kwiatkowski.
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.
Thorax, 55 (2000), pp. 1023-1027
[26.]
J. Lofgren, M. Ramet, M. Renko, R. Marttila, M. Hallman.
Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants.
J Infect Dis, 185 (2002), pp. 283-289
[27.]
J.T. McBride.
Pulmonary function changes in children after respiratory syncytial virus infection in infancy.
J Pediatr, 135 (1999), pp. 28-32
[28.]
C LCV Pardos Martínez, E. González Pérez-Yarza, C. Isanta Pomar, J. Fuertes Fernández-Espinar, J. Meriz Rubio.
Risk factors for asthma, allergy and bronchial hyperresponsiveness in children aged 6-8 years old.
An Esp Pediatr, 55 (2001), pp. 205-212
[29.]
G. Piedimonte.
Neural mechanisms of respiratory syncytial virus-induced inflammation and prevention of respiratory syncytial virus sequelae.
Am J Respir Crit Care Med, 163 (2001), pp. 18-21
[30.]
M. Silvestri, F. Sabatini, A.C. Defilippi, G.A. Rossi.
The wheezy infant-immunological and molecular considerations.
Paediatr Respir Rev, 5 (2004), pp. 81-87
[31.]
R.C. Welliver, L. Duffy.
The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years.
Pediatr Pulmonol, 15 (1993), pp. 19-27
[32.]
P. Sheeran, H. Jafri, C. Carubelli, J. Saavedra, C. Johnson, K. Krisher, et al.
Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease.
Pediatr Infect Dis J, 18 (1999), pp. 115-122
[33.]
C.B. Hall, K.R. Powell, N.E. MacDonald, C.L. Gala, M.E. Menegus, S.C. Suffin, et al.
Respiratory syncytial viral infection in children with compromised immune function.
N Engl J Med, 315 (1986), pp. 77-81
[34.]
G. Delage, P. Brochu, L. Robillard, G. Jasmin, J.H. Joncas, N. Lapointe.
Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome.
Arch Pathol Lab Med, 108 (1984), pp. 623-625
[35.]
E. Whimbey, R.B. Couch, J.A. Englund, et al.
Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia.
Clin Infect Dis, 21 (1995), pp. 376-379
[36.]
J.H. Aberle, S.W. Aberle, M.N. Dworzak, C.W. Mandl, W. Rebhandl, G. Vollnhofer, et al.
Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease.
Am J Respir Crit Care Med, 160 (1999), pp. 1263-1268
[37.]
R.P. Garofalo, J. Patti, K.A. Hintz, V. Hill, P.L. Ogra, R.C. Welliver.
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis.
J Infect Dis, 184 (2001), pp. 393-399
[38.]
J.P. Legg, I.R. Hussain, J.A. Warner, S.L. Johnston, J.O. Warner.
Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis.
Am J Respir Crit Care Med, 168 (2003), pp. 633-639
[39.]
H.A. Haeberle, W.A. Kuziel, H.J. Dieterich, A. Casola, Z. Gatalica, R.P. Garofalo.
Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology.
J Virol, 75 (2001), pp. 878-890
[40.]
H.S. Jafri, S. Chávez-Bueno, A. Mejías, A.M. Gómez, A.M. Ríos, S.S. Nassi, et al.
Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.
J Infect Dis, 189 (2004), pp. 1856-1865
[41.]
J. Schwarze, D.R. O’Donnell, A. Rohwedder, P.J. Openshaw.
Latency and persistence of respiratory syncytial virus despite T cell immunity.
Am J Respir Crit Care Med, 169 (2004), pp. 801-805
[42.]
H.A. Cubie, L.A. Duncan, L.A. Marshall, N.M. Smith.
Detection of respiratory syncytial virus nucleic acid in archival postmortem tissue from infants.
Pediatr Pathol Lab Med, 17 (1997), pp. 927-938
[43.]
T. Seemungal, R. Harper-Owen, A. Bhowmik, I. Moric, G. Sanderson, S. Message, et al.
Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 164 (2001), pp. 1618-1623
[44.]
S.C. Buckingham, H.S. Jafri, A.J. Bush, C.M. Carebelli, P. Sheeran, R.D. Hardy, et al.
A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome.
J Infect Dis, 185 (2002), pp. 1222-1228
[45.]
R. Malley, J. DeVincenzo, O. Ramilo, P.H. Dennehy, H.C. Meissner, W.C. Gruber, et al.
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.
J Infect Dis, 178 (1998), pp. 1555-1561
[46.]
R. Malley, L. Vernacchio, J. Devincenzo, O. Ramilo, P.H. Dennehy, H.C. Meissner, et al.
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions.
Pediatr Infect Dis J, 19 (2000), pp. 1-7
[47.]
D. Edell, V. Khoshoo, G. Ross, K. Salter.
Early ribavarin treatment of bronchiolitis: Effect on long-term respiratory morbidity.
Chest, 122 (2002), pp. 935-939
[48.]
D. Edell, E. Bruce, K. Hale, V. Khoshoo.
Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report.
Pediatr Pulmonol, 25 (1998), pp. 154-158
[49.]
S.E. Wenzel, R.L. Gibbs, M.V. Lehr, E.A. Simoes.
Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin.
Am J Med, 112 (2002), pp. 627-633
[50.]
J.L. Kimpen.
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
Respir Res, 3 (2002), pp. 40-45
[51.]
H. Bisgaard.
A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.
Am J Respir Crit Care Med, 167 (2003), pp. 379-383
[52.]
K.H. Hintz, M. Glori, R.C. Welliver, Welliver RC 2nd.
Sr. Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in mice.
J Infect Dis, 187 (2003), pp. 1773-1779
[53.]
A. Mejias, O. Ramilo.
Asthma and respiratory syncytial virus. Myth or reality?.
An Esp Pediatr, 57 (2002), pp. 199-204
[54.]
S. Chavez-Bueno, OK Mejías A, A.M. Ríos, M. Fonseca-Aten, J. Hatfield, A.M. Gómez, O. Ramilo, et al.
Respiratory syncytial virus (RSV)-induced long term airway hyperresponsiveness (AHR) is associated with viral persistence detected by real time polymerase chain reaction (RLT-PCR).
Pediatric Res, 1 (2004),
[55.]
A. Mejías, S. Chávez-Bueno, A.M. Ríos, J. Saavedra-Lozano, M. Fonseca Aten, J. Hatfield, et al.
Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.
Antimicrob Agents Chemother, 48 (2004), pp. 1811-1822
[56.]
H. Tsutsumi.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.
Pediatrics, 102 (1998), pp. 531-537
Copyright © 2004. Asociación Española de Pediatría
